Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Stock Based Compensation

Last Annual Value

5.11M

3-Year CAGR

%

5-Year CAGR

48%

10-Year CAGR

28%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Stock Based Compensation

SERA · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.11M
-1.0%10.3%N/A 
4.03M
-5.3%17.0%N/A
2.00M
-26.9%-17.0%9.5%
1.33M
7.3%21.1%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
17.44M
-6.0%66.2%N/A
4.81M
-12.9%N/A2.8%
2.22M
-30.4%-20.2%9.2%
4.32M
9.0%13.3%0.7%
2.61M
40.7%-2.0%2.7%
4.39B
763.1%240.4%N/A
6.42M
137.6%57.9%N/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245